SS-31 is also known as elamipretide. Its literature ranges from membrane biophysics to trials in people with particular mitochondrial disorders. These sources do not all answer the same question. A useful overview keeps the molecular rationale, unsuccessful trial outcomes and a narrowly defined regulatory development visible together.
Preserve the four-residue chemical definition
The supplied report identifies SS-31 as elamipretide and prints D-Arg-Dmt-Lys-Phe-NH2. The D-arginine and terminal amide are explicit parts of that description.Supplied SS-31 10 mg report (opens in a new tab)
Birk and colleagues’ mechanistic paper describes the corresponding dimethyltyrosine-containing peptide. Its sequence is a designed chemical entity, not simply four unspecified natural amino acids.Birk and colleagues — Cardiolipin, cytochrome c and mitochondrial ATP synthesis (opens in a new tab)
When comparing a source, retain the stereochemistry, modified residue and terminal group. A fluorescent derivative, different SS-family peptide or salt formulation needs its own material description.
The local report establishes what the supplied document says about its sample. It does not by itself show that the material is the formulated product used in a clinical trial or approved by a regulator.
What the cardiolipin experiments contribute
Birk and colleagues investigated SS-31 interactions using model lipid structures and mitochondrial preparations. They reported cardiolipin-associated effects on cytochrome c electron transfer, respiration and ATP synthesis in those systems.Birk and colleagues — Cardiolipin, cytochrome c and mitochondrial ATP synthesis (opens in a new tab)
This provides experimental support for a mitochondrial-membrane mechanism. It does not demonstrate that every illness involving mitochondrial dysfunction responds clinically to the peptide.
A later biophysical study by Mitchell and colleagues examined membrane interactions and found that surface charge helped determine binding behaviour. Such work refines the molecular picture rather than supplying a clinical efficacy result.Mitchell and colleagues — SS-31 binding to lipid bilayers and surface electrostatics (opens in a new tab)
Mechanism is useful for explaining why a trial was attempted. The trial still needs to test whether that biological rationale produces a meaningful effect in the actual disease population.
Retain the negative MMPOWER-3 result
The phase 3 MMPOWER-3 trial randomised 218 people with genetically confirmed primary mitochondrial myopathy. Its primary outcomes assessed six-minute walking distance and fatigue after 24 weeks.Karaa and colleagues — MMPOWER-3 randomised clinical trial (opens in a new tab)
Elamipretide did not improve those primary outcomes compared with placebo. That result should be included in a compound reference even when earlier laboratory findings are promising.Karaa and colleagues — MMPOWER-3 randomised clinical trial (opens in a new tab)
The relevant next question is which disease biology, population or outcome a new study tests. Combining different disorders under the word mitochondrial can conceal differences that matter to interpretation.
Understand the specific Barth syndrome milestone
FDA records show that Forzinity, a formulated elamipretide medicine, received US accelerated approval on 19 September 2025 to improve muscle strength in people with Barth syndrome weighing at least 30 kg.FDA — Forzinity drug trials snapshot (opens in a new tab)
The agency’s snapshot distinguishes the initial randomised period from its open-label extension. Superiority was not established on the initial walking and fatigue primary endpoints; the muscle-strength increases supporting approval were observed during the longer open-label period.FDA — Forzinity drug trials snapshot (opens in a new tab)
Accelerated approval included the requirement for further clinical confirmation. This is a disease-specific development, not evidence that SS-31 improves performance in healthy people or treats all mitochondrial conditions.FDA — Forzinity drug trials snapshot (opens in a new tab)
| Layer | Question |
|---|---|
| Membrane experiments | How the defined molecule behaves in experimental systems |
| Disease trial | Whether a measured patient outcome differs from its comparator |
| Regulatory decision | What was authorised for a specific formulated medicine |
A future update should identify the new trial or regulatory record and its date. It should preserve earlier results rather than replacing a mixed evidence history with an undifferentiated claim that the compound works.
Sources and further detail
- Supplied SS-31 10 mg report (opens in a new tab)
Complete supplied PDF read for the printed sequence and alias. No independent authentication or medicine-equivalence claim.
- Birk and colleagues — Cardiolipin, cytochrome c and mitochondrial ATP synthesis (opens in a new tab)
Original 2014 abstract and indexed experimental descriptions read. Model systems retained; mechanistic potential is not presented as clinical efficacy.
- Mitchell and colleagues — SS-31 binding to lipid bilayers and surface electrostatics (opens in a new tab)
Original 2020 abstract read for biophysical scope and surface-charge dependence. No clinical claim drawn from the membrane experiments.
- Karaa and colleagues — MMPOWER-3 randomised clinical trial (opens in a new tab)
Original indexed abstract and participant results checked alongside PubMed. The 218-person population and unsuccessful primary outcomes retained.
- FDA — Forzinity drug trials snapshot (opens in a new tab)
Official approval date, population, randomised/open-label distinction and accelerated-approval explanation read. No UK status or research-vial approval inferred.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.